|
Gene: AFF2 |
Gene summary for AFF2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | AFF2 | Gene ID | 2334 |
Gene name | AF4/FMR2 family member 2 | |
Gene Alias | FMR2 | |
Cytomap | Xq28 | |
Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | P51816 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2334 | AFF2 | RNA-P17T-P17T-2 | Human | Lung | IAC | 2.13e-03 | 5.69e-01 | 0.3371 |
2334 | AFF2 | RNA-P17T-P17T-4 | Human | Lung | IAC | 4.71e-02 | 5.08e-01 | 0.343 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Lung | AAH: Atypical adenomatous hyperplasia | |
AIS: Adenocarcinoma in situ | ||
IAC: Invasive lung adenocarcinoma | ||
MIA: Minimally invasive adenocarcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00434848 | Lung | IAC | regulation of RNA splicing | 49/2061 | 148/18723 | 4.76e-13 | 7.06e-10 | 49 |
GO:00083808 | Lung | IAC | RNA splicing | 75/2061 | 434/18723 | 4.89e-05 | 1.12e-03 | 75 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
AFF2 | SNV | Missense_Mutation | novel | c.774N>T | p.Leu258Phe | p.L258F | P51816 | protein_coding | deleterious(0.04) | probably_damaging(0.999) | TCGA-D7-A4Z0-01 | Stomach | stomach adenocarcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracilum | SD |
AFF2 | SNV | Missense_Mutation | c.2603A>C | p.Lys868Thr | p.K868T | P51816 | protein_coding | deleterious(0.05) | probably_damaging(0.979) | TCGA-EQ-8122-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD | |
AFF2 | SNV | Missense_Mutation | rs782756910 | c.3034N>A | p.Ala1012Thr | p.A1012T | P51816 | protein_coding | tolerated(0.52) | possibly_damaging(0.659) | TCGA-HU-A4GT-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Chemotherapy | copolang | SD |
AFF2 | SNV | Missense_Mutation | c.3413T>C | p.Met1138Thr | p.M1138T | P51816 | protein_coding | deleterious(0) | possibly_damaging(0.903) | TCGA-HU-A4GX-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | taxol | SD | |
AFF2 | SNV | Missense_Mutation | c.3308N>T | p.Ala1103Val | p.A1103V | P51816 | protein_coding | deleterious(0) | possibly_damaging(0.619) | TCGA-HU-A4H8-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Chemotherapy | didox | PD | |
AFF2 | SNV | Missense_Mutation | rs199567128 | c.716C>T | p.Pro239Leu | p.P239L | P51816 | protein_coding | deleterious(0) | possibly_damaging(0.467) | TCGA-IN-7808-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | PD |
AFF2 | SNV | Missense_Mutation | c.588N>A | p.Phe196Leu | p.F196L | P51816 | protein_coding | tolerated(1) | benign(0.001) | TCGA-IN-8663-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
AFF2 | SNV | Missense_Mutation | novel | c.2869N>C | p.Thr957Pro | p.T957P | P51816 | protein_coding | tolerated(0.07) | benign(0.105) | TCGA-KB-A6F7-01 | Stomach | stomach adenocarcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | CR |
AFF2 | SNV | Missense_Mutation | novel | c.797N>T | p.Ser266Leu | p.S266L | P51816 | protein_coding | tolerated(0.1) | benign(0.055) | TCGA-KB-A93H-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AFF2 | SNV | Missense_Mutation | novel | c.1021N>G | p.Thr341Ala | p.T341A | P51816 | protein_coding | deleterious(0.01) | possibly_damaging(0.63) | TCGA-R5-A7O7-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |